4-fluoro-α-methylphenylglycine | 252268-21-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-fluoro-α-methylphenylglycine
• 英文别名: 2-<4-Fluor-phenyl>-2-amino-propionsaeure；4-fluoro-α-phenyl-α-methylglycine；2-azaniumyl-2-(4-fluorophenyl)propanoate
• CAS: 252268-21-6
• 化学式: C₉H₁₀FNO₂
• 分子量: 183.182
• InChiKey: ORLSRSJHRJOCNH-UHFFFAOYSA-N

物化性质

• 沸点：
  296.0±30.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-fluoro-α-methylphenylglycine 、 二苯基膦 在 氢化钾 作用下， 以 乙二醇二甲醚 为溶剂， 反应 48.0h， 以75%的产率得到α-(4-diphenylphosphinophenyl)-α-methylglycine
  参考文献：
  名称：

  Water soluble phosphines

  摘要：

  Nucleophilic phosphination of the potassium or sodium salt of the fluorophenylalanines (1a, 2a) or -glycines (3a, 4a) with potassium phosphides Ph(R)PK (R = Me, Ph) yields chiral phosphine ligands (1-7) with amino acid moieties, The X-ray structure of 3 . 2H(2)O (space group Pbca) has been determined showing a betaine type structure for the amino acid moiety. The alpha-methyl derivatives of the phosphinophenylglycines (10, 11) were obtained in an analogous manner as 1-7, ortho- and para-Fluoroacetophenones have been employed as starting material for the syntheses of alpha-[4-fluorophenyl]-alpha-methylglycine (9c) and its ortho-isomer (8c). the X-ray structure of its monohydrate has been determined (space group P (1) over bar). The N-acetyl (3b, 8e) and ester derivatives (3d, 8d) of 3 and 8c are accessible using standard procedures. Resolution of the diastereomeric salt 12 obtained from (S)-(+)-2-hydroxymethylpyrrolidine and racem-8e by fractionated crystallization yielded the (S,R)-isomer. The absolute configuration of(S,R)-12 was determined by X-ray structural analysis (space group P2(1)2(1)2(1)). Cleavage of (S,R)-12 with hydrochloric acid gave enantiopure (R)-8e [alpha](D)(20) = - 30.9 degrees (c = 1, CH3OH). (C) 2000 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0022-328x(99)00689-0
• 作为产物：
  描述：

  5-(4-fluorophenyl)-5-methylhydantoin 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 48.0h， 以8.6%的产率得到4-fluoro-α-methylphenylglycine
  参考文献：
  名称：

  通过猪肾脏的D-氨基酸氧化酶将伯胺氧化氰化而合成伯[α]-氨基腈和非天然α-氨基酸的新酶法

  摘要：

  胺或氨基酸中氨基的氧化会激活sp 3 C [α- H小键]形成亚胺，使α碳原子成为亲核试剂（如氰化物）的优选靶标。

  DOI：

  10.1039/c6gc02003h

文献信息

• Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
  申请人：Rhone-Poulenc, Inc.

  公开号：US06344564B1

  公开（公告）日：2002-02-05

  Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones, processes for their preparation, fungicidal compositions containing them, and methods of using them to treat or prevent fungal disease in crops.

  杀真菌剂2-咪唑啉-5-酮和2-咪唑啉-5-硫酮，它们的制备方法，含有它们的杀真菌组合物，以及使用它们来治疗或预防作物真菌病的方法。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
  申请人：Galley Guido

  公开号：US20100120864A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X，Y，R1，R2和n如本文所定义，或其药学适宜的酸加盐。本发明还涉及含有此类化合物的制药组合物，以及用于治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍，应激相关障碍，精神疾病，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，物质滥用和代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和生物钟节律障碍以及心血管疾病。
• Potential Growth Antagonists. I. Hydantoins and Disubstituted Glycines^1,2
  作者：LOUIS H. GOODSON、IRWIN L. HONIGBERG、J. J. LEHMAN、W. H. BURTON

  DOI：10.1021/jo01081a024

  日期：1960.11
• PHOSPHIN-LIGANDEN MIT AMINOSÄUREGRUPPEN, EIN VERFAHREN ZU IHRER HERSTELLUNG SOWIE IHRE VERWENDUNG ALS KATALYSATORBESTANDTEILE
  申请人：Celanese Chemicals Europe GmbH

  公开号：EP0968216B1

  公开（公告）日：2002-10-16